What are the benefits and risks of pharmacologic and non‑pharmacologic therapies for acute kidney injury (AKI)?

Benefits and Risks of Pharmacological and Non-Pharmacological Therapies for AKI

The management of AKI relies primarily on supportive non-pharmacological strategies—fluid optimization, hemodynamic support, and nephrotoxin avoidance—as no specific pharmacological therapy has proven effective for preventing or treating AKI itself. 1, 2, 3

Non-Pharmacological Therapies

Fluid Management and Hemodynamic Support

Benefits:

• Balanced crystalloid solutions are preferred over 0.9% saline, though definitive evidence of harm from saline remains under investigation 1
• Appropriate fluid resuscitation maintains renal perfusion pressure and prevents progression of pre-renal azotemia
• Volume optimization can prevent AKI in perioperative and acute medical settings 1

Risks:

• Fluid overload is a critical pitfall that creates a vicious cycle of worsening kidney function 1
• Inappropriate attempts to "reverse" established AKI with aggressive fluid administration lead to pulmonary edema and increased mortality 1
• The presence of oliguria has multiple etiologies beyond hypovolemia; reflexive fluid administration without hemodynamic assessment causes harm 1
• In children, >10-15% fluid overload by body weight associates with adverse outcomes; adult thresholds remain poorly defined 1

Key Clinical Approach:

• Target cardiac filling pressures rather than arbitrary fluid volumes
• Monitor for fluid overload continuously and remove fluid promptly when indicated
• Avoid 0.9% saline when balanced solutions are available

Renal Replacement Therapy (RRT)

Benefits:

• Provides life-saving support for severe AKI with volume overload, electrolyte disturbances, or uremia
• Allows precise fluid removal when diuretics fail 1

Risks:

• Early initiation of RRT has not demonstrated mortality benefit in randomized trials 4
• Dialytrauma from RRT can impair renal recovery 5
• Timing, dose, and modality remain controversial with insufficient evidence for specific recommendations 1

Clinical Strategy:

• Initiate RRT for absolute indications (life-threatening hyperkalemia, severe acidosis, uremic complications, refractory volume overload)
• Avoid routine early initiation based solely on AKI stage
• Monitor for successful discontinuation indicators

Pharmacological Therapies

What NOT to Use (Strong Evidence Against)

Diuretics for AKI Prevention or Treatment:

• Do not use loop diuretics to prevent AKI (Grade 1B recommendation) 2
• Do not use diuretics to treat AKI except for volume overload management (Grade 2C) 2
• Despite theoretical benefits, randomized trials show furosemide does not prevent AKI and may increase mortality 2
• Exception: In hemodynamically stable patients with AKI and volume overload, diuretics may improve outcomes 2

Vasodilator Therapies:

• Do not use low-dose dopamine (Grade 1A) 2
• Do not use fenoldopam (Grade 2C) 2
• Do not use atrial natriuretic peptide (Grade 2B-2C) 2
• Animal studies showed promise, but human trials failed to demonstrate benefit 2

Growth Factors:

• Do not use recombinant human IGF-1 (Grade 1B) 2

Contrast-Associated AKI Prevention:

• Do not use sodium bicarbonate solutions or N-acetylcysteine for contrast prophylaxis—the PRESERVE trial definitively showed no benefit 1
• Modern contrast agents carry far lower risk than previously believed 1
• Never withhold necessary contrast studies in life-threatening conditions due to AKI concerns 1

Nephrotoxic Drug Management (Critical Non-Pharmacological Strategy)

Benefits of Drug Stewardship:

• Avoiding nephrotoxic combinations (the "triple whammy" of ACE-I/ARB + diuretics + NSAIDs) reduces AKI incidence 1
• Electronic surveillance systems identifying patients on ≥3 nephrotoxic drugs have sustainably decreased AKI rates 1
• Proper aminoglycoside dosing (single daily dose preferred) and monitoring reduces toxicity 2

Risks of Poor Drug Management:

• NSAIDs cause both hemodynamic dysfunction and direct tubular injury 1
• Aminoglycosides, acyclovir, and VEGF antagonists cause direct tubular injury 1
• ACE-I/ARBs cause hemodynamic dysfunction without direct injury but are actually renoprotective long-term 1
• Drug accumulation in AKI leads to toxicity; underdosing leads to therapeutic failure 1

Critical Clinical Algorithm:

1. Audit all medications daily for nephrotoxic potential
2. Discontinue nephrotoxic drugs unless absolutely necessary for life-threatening conditions 1
3. Use topical/local aminoglycosides rather than IV when feasible 2
4. Monitor drug levels for aminoglycosides: after 24h for multiple daily dosing, after 48h for single daily dosing 2
5. Adjust doses for changing renal function and RRT clearance
6. Timing of ACE-I/ARB discontinuation and reinitiation remains under investigation but should be individualized to clinical context (heart failure, sepsis, surgery) 1

Emerging Pharmacological Approaches (Investigational)

Potential Future Therapies:

• Recombinant alkaline phosphatase shows early promise 6
• Remote ischemic preconditioning may have protective effects 6, 7
• Amino acid supplementation is under investigation 7
• Various compounds targeting inflammation, oxidative stress, and hemodynamics are in trials 8

Current Status:

• No pharmacological therapy is currently recommended for routine clinical use 4, 8, 3
• Recognition of AKI sub-endotypes may enable targeted therapies in the future 8

Common Pitfalls to Avoid

1. Biomarker-positive states do not automatically indicate need for volume replacement—early renal injury markers should guide monitoring, not reflexive fluid administration 1

2. Oliguria has multiple causes beyond hypovolemia—assess hemodynamics before giving fluids 1

3. Do not withhold life-saving interventions (contrast studies, necessary nephrotoxic antibiotics) due to AKI concerns 1

4. Return of creatinine to baseline does not exclude nephron loss—AKI survivors need long-term follow-up for CKD and cardiovascular risk 7, 5

5. Sodium bicarbonate for metabolic acidosis in AKI remains controversial and requires further study 1

Evidence Quality and Gaps

The 2020 KDIGO conference [1-1] and 2012 KDIGO guidelines 2 represent the highest-quality guidance available. However, critical knowledge gaps persist regarding optimal fluid targets, vasopressor choice, RRT timing, and ACE-I/ARB management 1. The evidence consistently shows what NOT to do (diuretics, dopamine, contrast prophylaxis) but provides limited positive guidance on specific interventions beyond supportive care 2, 3.

The cornerstone of AKI management remains: treat the underlying cause, optimize hemodynamics without causing fluid overload, eliminate nephrotoxins, and provide RRT only when absolutely indicated. 4, 9, 3